PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma
Our study identifies PTEN deficiency and ERBB2/ERBB3-mediated reactivation as key resistance mechanisms to MET inhibition in MET-amplified HCC. The findings support biomarker-informed combination strategies and underscore the importance of stratifying patients based on MET amplification status.
Authors
- Shujie Zhan
- Xiao Hu (ORCID: https://orcid.org/0000-0003-1128-4099)
- Haigang Geng (ORCID: https://orcid.org/0009-0009-5765-5992)
- Long Liao (ORCID: https://orcid.org/0000-0002-9150-2377)
- Qingsong Ye (ORCID: https://orcid.org/0000-0002-2868-9247)
- Linmeng Zhang
- Ruolan Qian (ORCID: https://orcid.org/0000-0002-9739-029X)
- Yuchen Guo (ORCID: https://orcid.org/0000-0003-2108-6635)
- Ying Cao (ORCID: https://orcid.org/0000-0003-3201-9817)
- Quan Zheng (ORCID: https://orcid.org/0000-0002-4512-9233)
- Ling Jing (ORCID: https://orcid.org/0000-0002-4919-8121)
- Yang Ge (ORCID: https://orcid.org/0000-0001-7299-6175)
Institutions
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
- Ruijin Hospital (CN)
- Shanghai Cancer Institute (CN)
- Shanghai First People's Hospital (CN)
- State Key Laboratory of Oncogene and Related Genes (CN)
Publication Details
- Journal
- Cellular Oncology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1007/s13402-025-01097-y
- Citations
- 1
- Primary Topic
- Liver physiology and pathology
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Shanghai Jiao Tong University